“We support the underlying goal of enhancing transparency,” the group said in a letter, but the rule “will result in the publication of misleading information and impose costly and burdensome paperwork requirements on physicians while shedding very little light on actual physician-industry interactions.”
During the Jan. 17 meeting with Office of Management and Budget (OMB) and Department of Health and Human Services (HHS) officials, the AMA also argued that the reports could result in inaccurate information with no oversight and the implication that doctors are engaging in illegal or unethical activities.
“This perception has the potential to chill beneficial collaboration and information exchange between physicians and industry,” the group said in a letter to officials, posted on the OIRA website.
OIRA is required to list meetings it has with lobbyists involved in the regulatory process and often posts letters other written materials used in the meetings.
Last month, officials also met with the Union of Concerned Scientists, the National Research Center for Women and Families, the Consumers Union and GE Healthcare. According to the OIRA website, individuals from OMB, HHS, OIRA and the White House Domestic Policy Council have been involved.
In the posted meeting materials, GE Healthcare provided a one-page recommendation for the implementation of the rule that mostly revolved around clarifying how items are reported — for example, using common or generic names of medical devices and drugs instead of clinical names. They also asked for more time to put the tracking databases into place.
But others would like to see the process move faster, claiming that it would help curb fraud in Medicare.
Earlier this month, AARP, the AFL-CIO and 17 other healthcare advocacy groups wrote a letter to OMB asking it to speed along the rule approval. The American Medical Student Association and the National Physicians Alliance wrote a similar letter to Jack Lew, President Obama's chief of staff.
In addition, Sen. Chuck Grassley (R-Iowa), who co-authored the Physician Payments Sunshine Act with former Sen. Herb Kohl (D-Wis.), wrote to Lew and pressured the administration to finalize the rules.